Xin Chen
University of Michigan
4 Papers
Xin Chen is an academic researcher from University of Michigan. The author has contributed to research in topics: Cancer research & Medicine. The author has an hindex of 2, co-authored 2 publications. Previous affiliations of Xin Chen include Wuhan University.
Chat about Author
Papers
Therapeutic Efficacy of Cancer Stem Cell Vaccines in the Adjuvant Setting.
Yangyang Hu,Lin Lu,Yang Xia,Xin Chen,Alfred E. Chang,Robert E. Hollingsworth,Elaine M. Hurt,John H. Owen,Jeffrey S. Moyer,Mark E. Prince,Fu Dai,Yangyi Bao,Yi Wang,Joel Whitfield,Jian Chuan Xia,Shiang Huang,Max S. Wicha,Qiao Li +17 more
TL;DR: Overall, the results offered a preclinical proof of concept for the use of ALDH(high) CSC-DC vaccines in the adjuvant setting to more effectively limit local tumor recurrence and spontaneous pulmonary metastasis, as compared with traditional DC vaccines, with increased host survival further accentuated by simultaneous PD-L1 blockade.
Prognostic value of circulating tumor DNA using target next-generation sequencing in extensive-stage small-cell lung cancer.
Jiexia Zhang,Ningning Zhou,Huojin Deng,Xin Chen,Qunqing Chen,Qiongyao Wang,Lei Sun,Yang Wen,Xiaolong Cao,Zhiqiang Luo,Jian Zhang,Weiliang Zhu,Linlang Guo +12 more
TL;DR: In this paper , the authors performed next-generation sequencing of 159 plasma samples from 69 patients with extensive-stage lung cancer (SCLC) and quantified circulating tumor (ct)DNA levels in haploid genome equivalents per mL (hGE/mL).
IL-2 augments the therapeutic efficacy of adoptively transferred B cells which directly kill tumor cells via the CXCR4/CXCL12 and perforin pathways
Yang Xia,Huimin Tao,Huimin Tao,Huimin Tao,Yangyang Hu,Yangyang Hu,Quanning Chen,Quanning Chen,Xin Chen,Xin Chen,Leiming Xia,Li Zhou,Li Zhou,Yi Wang,Yangyi Bao,Shiang Huang,Xiubao Ren,Steven K. Lundy,Fu Dai,Qiao Li,Alfred E. Chang +20 more
TL;DR: Additional transwell experiments showed that effector B cells could directly kill tumor cells in cell-cell contact via the Fas/FasL and CXCR4/CXCL12 pathways as well as perforin, while without cell contact,perforin secreted by B cells led to tumor cell cytotoxicity.
miR-22 gene therapy treats HCC by promoting anti-tumor immunity and enhancing metabolism.
TL;DR: Chen et al. as discussed by the authors showed that miR-22 delivered by adeno-associated virus serotype 8 effectively treated HCC and achieved better survival outcomes without noticeable toxicity compared with FDA-approved lenvatinib.